AGM 2020 Video, page-13

Hi all
A post as I had some time to spare. I posted a bit on RAC some months ago. I was one of the early investors. Please see earlier posts to expand on the following points. I made good money here and am very happy others did even better. The share price rise has been stellar. I am however a little concerned re the future.
1. company has done new preclinical work on an indication (breast cancer) that has already been in clinical studies. This implies to me that the earlier preclinical data has not been accepted as there was no need to repeat it. FTO component of study not powered so not helpful. We already knew Bisantrene works in preclinical breast cancer.
2. Doxorubicin costs around $100 per dose. Comparing Bisantrene to monoclonal or checkpoint inhibitor prices is not sensible. The price per dose of this drug will be very cheap.
3. there are other analogies of bisantrene and very similar cyclical structures being developed
4. If Bisantrene was going to be bought out as a chemo drug based on lowered side effects without another significant / pivotal trial being performed I don’t see why this has not already happened. Thus I see another pivotal (or several) trials needed if that is the catalyst
5. The company can not fund the trials needed with current funds. It needs to be bought out or raise significant money (as the share price is so high it would be a good time now)
6. I do not understand why good board members / original driver left recently.
7. The share price rise was based on the checkpoint inhibition mechanism of action seen in the COH paper. It was very good but it is not acting as a chemotherapy agent but rather an immunotherapy agent. This is the big advance in the story. However the mice were given activated T cells as well to get the response. Thus Car-t or another like tech is needed.
8. The other drug in the COH study that worked just as well finishes its phase 1/2a trial this month (27 patients). It is oral, does not need a central line placement and is cheap. Which drug would a big pharma take over? More variables here than price and ease of use to be sure but worth thinking about.
9. There has been an air of PR here that caused me to reflect.
Anyway, just ignore me, call me a troll-don’t really care. I truly hope everyone makes money here and I hope everyone has a great Christmas. A buy out seems to be the sensible way forward rather than further clinical development. I just thought that as any negative posts seem to be shot down so hard I would try a post that outlines the concerns some have in case anyone was interested.